Prosper I. Okonkwo, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Nigeria | 47 | 2023 | 733 | 1.680 |
Why?
|
HIV Infections | 45 | 2023 | 16715 | 1.260 |
Why?
|
Anti-HIV Agents | 20 | 2023 | 4255 | 1.100 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 1 | 2021 | 92 | 0.760 |
Why?
|
Anti-Retroviral Agents | 10 | 2022 | 1714 | 0.750 |
Why?
|
Medication Adherence | 9 | 2021 | 2063 | 0.690 |
Why?
|
Viral Load | 19 | 2023 | 3300 | 0.610 |
Why?
|
Drug Resistance, Viral | 6 | 2020 | 820 | 0.580 |
Why?
|
HIV-1 | 11 | 2023 | 6939 | 0.480 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2021 | 912 | 0.450 |
Why?
|
Mycobacterium tuberculosis | 1 | 2021 | 1832 | 0.370 |
Why?
|
Infectious Disease Transmission, Vertical | 4 | 2016 | 1320 | 0.310 |
Why?
|
Lost to Follow-Up | 3 | 2020 | 105 | 0.290 |
Why?
|
Antiretroviral Therapy, Highly Active | 6 | 2019 | 1872 | 0.280 |
Why?
|
Capacity Building | 2 | 2019 | 248 | 0.270 |
Why?
|
Universities | 4 | 2020 | 956 | 0.270 |
Why?
|
Developing Countries | 5 | 2023 | 2815 | 0.250 |
Why?
|
Pregnancy Complications, Infectious | 5 | 2016 | 2026 | 0.240 |
Why?
|
Research Personnel | 2 | 2019 | 573 | 0.230 |
Why?
|
CD4 Lymphocyte Count | 9 | 2021 | 2560 | 0.230 |
Why?
|
Rifabutin | 2 | 2021 | 52 | 0.220 |
Why?
|
Chemoprevention | 2 | 2015 | 319 | 0.210 |
Why?
|
Ritonavir | 2 | 2021 | 322 | 0.190 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2023 | 2020 | 0.190 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2020 | 941 | 0.190 |
Why?
|
Faculty | 2 | 2023 | 386 | 0.190 |
Why?
|
Ambulatory Care Facilities | 4 | 2020 | 934 | 0.180 |
Why?
|
Antibiotics, Antitubercular | 1 | 2019 | 104 | 0.170 |
Why?
|
Cost of Illness | 1 | 2008 | 1860 | 0.160 |
Why?
|
Health Services | 1 | 2023 | 758 | 0.160 |
Why?
|
Biomedical Research | 3 | 2020 | 3309 | 0.150 |
Why?
|
Publications | 1 | 2020 | 195 | 0.150 |
Why?
|
Tuberculosis | 2 | 2021 | 1912 | 0.150 |
Why?
|
Delivery of Health Care | 3 | 2021 | 5321 | 0.150 |
Why?
|
Zidovudine | 2 | 2016 | 620 | 0.150 |
Why?
|
Efficiency | 1 | 2020 | 462 | 0.140 |
Why?
|
National Health Programs | 1 | 2019 | 445 | 0.140 |
Why?
|
Adult | 30 | 2021 | 214056 | 0.130 |
Why?
|
Adolescent Health Services | 1 | 2017 | 215 | 0.130 |
Why?
|
Microbial Sensitivity Tests | 1 | 2021 | 1877 | 0.130 |
Why?
|
Self Care | 2 | 2017 | 786 | 0.130 |
Why?
|
Telemedicine | 2 | 2023 | 2872 | 0.130 |
Why?
|
Nevirapine | 1 | 2015 | 267 | 0.120 |
Why?
|
Program Development | 1 | 2020 | 1316 | 0.120 |
Why?
|
Acetic Acid | 2 | 2023 | 55 | 0.120 |
Why?
|
Humans | 53 | 2023 | 744376 | 0.110 |
Why?
|
Antitubercular Agents | 1 | 2021 | 1320 | 0.110 |
Why?
|
Health Priorities | 1 | 2016 | 380 | 0.110 |
Why?
|
Female | 38 | 2023 | 380200 | 0.110 |
Why?
|
Viremia | 1 | 2016 | 736 | 0.110 |
Why?
|
Retrospective Studies | 18 | 2022 | 77459 | 0.110 |
Why?
|
Renal Insufficiency | 1 | 2019 | 804 | 0.110 |
Why?
|
Appointments and Schedules | 1 | 2016 | 417 | 0.110 |
Why?
|
Pharmacy | 1 | 2014 | 91 | 0.110 |
Why?
|
Health Resources | 2 | 2020 | 911 | 0.110 |
Why?
|
Male | 34 | 2023 | 350118 | 0.110 |
Why?
|
Hospital Information Systems | 1 | 2014 | 395 | 0.100 |
Why?
|
Health Plan Implementation | 1 | 2014 | 352 | 0.100 |
Why?
|
Genotype | 4 | 2020 | 12952 | 0.100 |
Why?
|
Adolescent | 14 | 2023 | 85784 | 0.090 |
Why?
|
Peptide Hydrolases | 1 | 2013 | 634 | 0.090 |
Why?
|
Young Adult | 12 | 2021 | 56434 | 0.090 |
Why?
|
Mutation, Missense | 1 | 2019 | 2566 | 0.090 |
Why?
|
Mental Health Services | 1 | 2020 | 1643 | 0.080 |
Why?
|
Medical Records Systems, Computerized | 1 | 2014 | 1205 | 0.080 |
Why?
|
International Cooperation | 1 | 2014 | 1420 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2017 | 1438 | 0.070 |
Why?
|
Quality Improvement | 2 | 2019 | 3749 | 0.070 |
Why?
|
Drug Prescriptions | 1 | 2016 | 1637 | 0.070 |
Why?
|
Education, Medical | 2 | 2020 | 1722 | 0.070 |
Why?
|
Continuity of Patient Care | 3 | 2020 | 1049 | 0.070 |
Why?
|
Salvage Therapy | 1 | 2013 | 1275 | 0.070 |
Why?
|
Selection Bias | 1 | 2008 | 371 | 0.070 |
Why?
|
Africa South of the Sahara | 2 | 2022 | 724 | 0.070 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3610 | 0.070 |
Why?
|
Treatment Outcome | 11 | 2020 | 63115 | 0.070 |
Why?
|
Mentors | 2 | 2023 | 631 | 0.070 |
Why?
|
Middle Aged | 11 | 2021 | 213388 | 0.070 |
Why?
|
Drug Monitoring | 1 | 2011 | 956 | 0.070 |
Why?
|
Qualitative Research | 3 | 2019 | 2682 | 0.060 |
Why?
|
Point-of-Care Systems | 2 | 2023 | 1178 | 0.060 |
Why?
|
Cross-Sectional Studies | 6 | 2021 | 25041 | 0.060 |
Why?
|
Data Collection | 2 | 2014 | 3339 | 0.060 |
Why?
|
Health Services Accessibility | 2 | 2017 | 5135 | 0.060 |
Why?
|
Family Characteristics | 1 | 2008 | 1000 | 0.060 |
Why?
|
Morbidity | 1 | 2008 | 1768 | 0.050 |
Why?
|
Treatment Failure | 2 | 2020 | 2618 | 0.050 |
Why?
|
Health Policy | 3 | 2019 | 2661 | 0.050 |
Why?
|
HIV | 2 | 2023 | 1604 | 0.050 |
Why?
|
Spouse Abuse | 1 | 2002 | 178 | 0.050 |
Why?
|
Cohort Studies | 6 | 2020 | 40558 | 0.050 |
Why?
|
Mental Disorders | 1 | 2020 | 6600 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2014 | 3842 | 0.050 |
Why?
|
Review Literature as Topic | 1 | 2022 | 336 | 0.050 |
Why?
|
Fees and Charges | 1 | 2020 | 195 | 0.040 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2008 | 2232 | 0.040 |
Why?
|
Early Detection of Cancer | 2 | 2023 | 3086 | 0.040 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 39 | 0.040 |
Why?
|
Hospitals, Teaching | 2 | 2020 | 1180 | 0.040 |
Why?
|
Infant, Newborn | 5 | 2019 | 25628 | 0.040 |
Why?
|
Cooperative Behavior | 2 | 2018 | 1504 | 0.040 |
Why?
|
Socioeconomic Factors | 2 | 2013 | 7785 | 0.040 |
Why?
|
Organizations | 1 | 2019 | 170 | 0.040 |
Why?
|
Infant | 5 | 2020 | 35134 | 0.040 |
Why?
|
Patient Dropouts | 1 | 2020 | 421 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2020 | 13988 | 0.040 |
Why?
|
Mutation | 2 | 2020 | 29786 | 0.040 |
Why?
|
Social Support | 2 | 2017 | 2118 | 0.040 |
Why?
|
Disclosure | 1 | 2023 | 736 | 0.040 |
Why?
|
Social Stigma | 1 | 2023 | 701 | 0.040 |
Why?
|
Case-Control Studies | 2 | 2020 | 21747 | 0.040 |
Why?
|
Caregivers | 1 | 2008 | 2095 | 0.040 |
Why?
|
Pregnancy | 5 | 2016 | 29144 | 0.030 |
Why?
|
RNA, Viral | 2 | 2015 | 2901 | 0.030 |
Why?
|
Unsafe Sex | 1 | 2017 | 220 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2019 | 4805 | 0.030 |
Why?
|
Drug Interactions | 1 | 2019 | 1460 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 1 | 2008 | 3020 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2019 | 764 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2020 | 12244 | 0.030 |
Why?
|
Primary Health Care | 2 | 2017 | 4557 | 0.030 |
Why?
|
Self Efficacy | 1 | 2017 | 616 | 0.030 |
Why?
|
Research Support as Topic | 1 | 2018 | 705 | 0.030 |
Why?
|
Logistic Models | 1 | 2008 | 13409 | 0.030 |
Why?
|
Peer Group | 1 | 2017 | 635 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2017 | 681 | 0.030 |
Why?
|
Focus Groups | 1 | 2016 | 1321 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2017 | 1462 | 0.030 |
Why?
|
Glomerular Filtration Rate | 1 | 2019 | 2166 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3557 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2016 | 2887 | 0.020 |
Why?
|
Child | 4 | 2021 | 77708 | 0.020 |
Why?
|
Patient Compliance | 1 | 2020 | 2685 | 0.020 |
Why?
|
Patient Preference | 1 | 2016 | 889 | 0.020 |
Why?
|
Adolescent Behavior | 1 | 2017 | 1151 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2460 | 0.020 |
Why?
|
Hospitalization | 1 | 2008 | 10259 | 0.020 |
Why?
|
Health Services Research | 1 | 2016 | 1836 | 0.020 |
Why?
|
Leadership | 1 | 2018 | 1357 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4933 | 0.020 |
Why?
|
Age Factors | 2 | 2016 | 18373 | 0.020 |
Why?
|
HIV Antibodies | 1 | 2015 | 1322 | 0.020 |
Why?
|
Health Expenditures | 1 | 2020 | 2349 | 0.020 |
Why?
|
Quality Indicators, Health Care | 1 | 2017 | 1831 | 0.020 |
Why?
|
Risk Factors | 3 | 2021 | 72295 | 0.020 |
Why?
|
Prevalence | 2 | 2020 | 15221 | 0.020 |
Why?
|
Prospective Studies | 2 | 2023 | 53291 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2013 | 2715 | 0.020 |
Why?
|
Regression Analysis | 1 | 2016 | 6459 | 0.020 |
Why?
|
Patient Care Team | 1 | 2017 | 2531 | 0.020 |
Why?
|
Prenatal Care | 1 | 2013 | 1092 | 0.020 |
Why?
|
Phylogeny | 1 | 2013 | 2804 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10388 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6539 | 0.020 |
Why?
|
Time Factors | 2 | 2017 | 40077 | 0.020 |
Why?
|
Communication | 1 | 2018 | 3750 | 0.010 |
Why?
|
Mental Health | 1 | 2017 | 3014 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2015 | 39052 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2020 | 4468 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 3922 | 0.010 |
Why?
|
Research Design | 1 | 2017 | 5986 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8386 | 0.010 |
Why?
|
Marital Status | 1 | 2002 | 437 | 0.010 |
Why?
|
Marriage | 1 | 2002 | 339 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 18111 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2014 | 4369 | 0.010 |
Why?
|
Rural Health Services | 1 | 2002 | 379 | 0.010 |
Why?
|
Mass Screening | 1 | 2013 | 5255 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14723 | 0.010 |
Why?
|
Quality of Life | 1 | 2017 | 12803 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2011 | 15078 | 0.010 |
Why?
|
Educational Status | 1 | 2002 | 2540 | 0.010 |
Why?
|
Child, Preschool | 1 | 2015 | 41005 | 0.010 |
Why?
|
Emotions | 1 | 2002 | 2658 | 0.010 |
Why?
|